The primary endpoint of the study was to assess if the change from baseline in HbA1c achieved with ONGLYZA 5 mg per day was non-inferior (defined in the study protocol as a treatment group numerical ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...

WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA(TM) (sitagliptin), the only DPP-4 inhibitor ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with ...

Type II diabetes costs the NHS £8.8 billion a year. Novo Nordisk has announced that its oral semaglutide improved glycaemic control in people with type II diabetes across baseline HbA1c levels in the ...

MUNICH -- For type 2 diabetes patients uncontrolled on metformin and sitagliptin (Januvia), adding the novel sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin improved glycemic levels, a ...

Unichem has obtained tentative approval from the Food and Drug Administration for sitagliptin tablets in dosage strengths of 25 mg, 50 mg, and 100 mg The medication is a generic of Merck Sharpe and ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin ...

In terms of controlling Type 2 diabetes and potentially obesity, Boston’s Intarcia Therapeutics just released some impressive Phase 3 findings: Its implantable device has been found to be more ...

COPENHAGEN, June 26 (Reuters) - Novo Nordisk said on Saturday extension data from a study showed its new diabetes drug Victoza provided better blood sugar control and also weight reduction than ...